1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025

  • November 2016
  • 67 pages
  • ID: 4519594
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025

Summary

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (IARC, 2016). Lung cancer is classified into three main types: non-small cell lung cancer (NSCLC), small cell lung cancer, and lung carcinoid tumor. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. Small cell lung cancer accounts for 10–15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than 5% of lung cancers (ACS, 2016).

In the 8MM, the diagnosed incident cases of NSCLC will increase from 791,563 cases in 2015 to 1,069,516 cases in 2025, at an Annual Growth Rate (AGR) of 3.51% per year. In the five major European markets (5EU: France, Germany, Italy, Spain, and the UK), the diagnosed incident cases of NSCLC will increase from 172,998 cases in 2015 to 194,435 cases in 2025, at an AGR of 1.24%.

In 2015, there were 1,199,845 five-year diagnosed prevalent cases of NSCLC in the 8MM, which is expected to increase to 1,626,132 cases by 2025, at an AGR of 3.55%. Among the 8MM, China had the highest number of five-year diagnosed prevalent cases of NSCLC in 2015 and 2025, at 439,438 cases and 708,530 cases, respectively, and will have the highest growth in the 8MM at an AGR of 6.12%.

The relative survival of NSCLC varies by subtype, where adenocarcinoma has the highest survival, followed by squamous cell carcinoma, and large cell carcinoma. In the alternate forecast, due to the forecast increase in adenocarcinoma during 2015–2025, epidemiologists expect an increase in relative survival and, consequently, an increase in the number of five-year diagnosed prevalent cases of NSCLC.

The report “EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2025” provides an overview of the risk factors and the global and historical trends for NSCLC in the eight major markets (8MM): US, France, Germany, Italy, Spain, UK, Japan, China (urban). It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of NSCLC in these markets from 2015–2025. The incident cases are further segmented by sex and age (18–39 years, 40–59 years, 60–79 years, and 80 years and older), cancer stage at diagnosis (IA, IB, IIA, IIB, IIIA, IIIB, and IV), cancer histology subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other). Moreover, this report provides an alternate forecast scenario that takes into account potential changes in the diagnosed incident cases distribution by histology subtype. The alternate forecast also examines the impact of potential changes in histology subtypes on the 10-year epidemiology forecast of the five-year prevalent cases of NSCLC from 2015–2025.

Scope

- The Non-Small Cell Lung Cancer (NSCLC) EpiCast Report provides an overview of the risk factors and global trends of NSCLC in the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It also includes a 10-year epidemiology forecast of the diagnosed incident and five-year diagnosed prevalent cases of NSCLC in these markets from 2015-2025. The incident cases are further segmented by sex and age, cancer stage at diagnosis (IA, IB, IIA, IIB, IIIA, IIIB, and IV), cancer histology subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other), and the presentation of the biomarker mutations by histology subtype (EGFR, KRAS, ALK, METExon 14, PIK3CA, BRAF V600E, and ROS1). The report also provides an alternate forecast scenario that takes into account potential changes in the diagnosed incident cases distribution by histology subtype.
- The NSCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The NSCLC EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
- Quantify patient populations in the global NSCLC market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for NSCLC therapeutics in each of the markets covered.
- Compare patient population potentials due to potential changes in histology subtypes.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Malignant Pleural Effusion - Pipeline Review, H2 2019

Malignant Pleural Effusion - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Malignant Pleural Effusion - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Malignant Pleural Effusion - Pipeline Review, H2 2019, provides an overview ...

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2019SummaryC-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide ...

NT 3 Growth Factor Receptor - Pipeline Review, H2 2019

NT 3 Growth Factor Receptor - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

NT 3 Growth Factor Receptor - Pipeline Review, H2 2019SummaryNT 3 Growth Factor Receptor (TrkC Tyrosine Kinase or GP145 TrkC or Neurotrophic Tyrosine Kinase Receptor Type 3 or NTRK3 or EC 2.7.10.1) pipeline ...


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on